Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-PET

clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related to

our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in our Form S3 Amendment No. 3 filed with the SEC

October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light o
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (PRWEB) July 22, 2014 OHAUS ... portable, and mechanical balances and scales, proudly announces ... has won Laboratory Equipment magazine’s 2014 “Readers' Choice” ... second consecutive year the Explorer was voted the ... annual Readers’ Choice Awards celebrates “excellence in product ...
(Date:7/22/2014)... Massachusetts e SHENZHEN , ... Co., LTD, (BGI Tech), una filiale di BGI, la ... lancio mondiale di un nuovo servizio di sequenziamento dell,intero ... di Complete Genomics. Complete Genomics, molto ... tecnologie di sequenziamento proprietarie con il 99.999% di precisione ...
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... , July 22, 2014  The Broad ... million from philanthropist Ted Stanley aimed ... bringing new treatments based on molecular understanding to ... The Stanley commitment – the ... largest for scientific research in general – will ...
Breaking Biology Technology:OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10
... 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical ... today announced its third quarter financial results for 2011. ... Nile reported research and development collaboration income relating to ... to none in the third quarter of 2010. The ...
... 13, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... 8th Annual Healthcare Conference to be held November 15 to ... Pharmasset,s President and Chief Executive Officer, will provide an overview ... (ET). To access a simultaneous webcast of Mr. ...
... 2011 Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies -- today reported financial results for the three ... Recent and Upcoming Highlights ...
Cached Biology Technology:Nile Therapeutics Reports 2011 Third Quarter Financial Results 2Nile Therapeutics Reports 2011 Third Quarter Financial Results 3Nile Therapeutics Reports 2011 Third Quarter Financial Results 4Nile Therapeutics Reports 2011 Third Quarter Financial Results 5Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Spherix Announces Third Quarter Financial Results 2Spherix Announces Third Quarter Financial Results 3Spherix Announces Third Quarter Financial Results 4Spherix Announces Third Quarter Financial Results 5Spherix Announces Third Quarter Financial Results 6Spherix Announces Third Quarter Financial Results 7
(Date:7/22/2014)... 2014) New research from the Monell Center reveals ... can increase airway inflammation in asthmatics for at least ... that expectations can play in health-related outcomes. , "Asthmatics ... expect that an odor is harmful, our bodies react ... lead author Cristina Jan, PhD, a Monell physiologist. "Both ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... to dust mites (and chances are you are), help ... University of Iowa have developed a vaccine that can ... response. In animal tests, the nano-sized vaccine package lowered ... the allergens, according to the paper, published in the ... Journal . One big reason why it works, the ...
Breaking Biology News(10 mins):In asthma, it's not just what you smell, but what you think you smell 2In asthma, it's not just what you smell, but what you think you smell 3Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Researchers create vaccine for dust-mite allergies 2
... (Boston) A new study from Boston University School ... pluripotent stem (iPS) cells in an experimental model were ... The study, published online in Cell Stem Cell ... develop cell types that could offer treatment for a ...
... new study that provides surprising details on changes in Earth,s ... last interglacial--the period between "ice ages"--was warmer than previously thought ... greenhouse gases increase in the atmosphere and global temperatures rise. ... the massive West Antarctic ice sheet may have contributed more ...
... led by Associate Professor Kenji Osafune and his colleague ... and Application (CiRA), Kyoto University in Japan, has succeeded ... induced pluripotent stem (iPS) cells to differentiate into intermediate ... lineages. This represents a major step toward realizing renal ...
Cached Biology News:BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 3Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 4Monitoring and robust induction of nephrogenic intermediate mesoderm from human iPSCs 2
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... an evolutionarily conserved form of cell suicide, ... The central component of this process is ... These enzymes participate in a series ... to pro-apoptotic signals and result in the ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
...
Biology Products: